X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (101696) 101696
Magazine Article (391) 391
Book Chapter (389) 389
Book / eBook (98) 98
Newsletter (74) 74
Publication (47) 47
Newspaper Article (27) 27
Dissertation (22) 22
Conference Proceeding (21) 21
Book Review (17) 17
Web Resource (15) 15
Trade Publication Article (7) 7
Reference (5) 5
Paper (4) 4
Government Document (3) 3
Streaming Video (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (80109) 80109
male (49555) 49555
female (41665) 41665
middle aged (36193) 36193
cardiac & cardiovascular systems (32452) 32452
aged (31291) 31291
myocardial-infarction (23789) 23789
myocardial infarction - drug therapy (23721) 23721
animals (18392) 18392
risk factors (18142) 18142
myocardial infarction (17175) 17175
mortality (16151) 16151
treatment outcome (15620) 15620
adult (15593) 15593
acute myocardial-infarction (14465) 14465
time factors (11498) 11498
heart attacks (11386) 11386
cardiology (10081) 10081
cardiovascular disease (9791) 9791
medicine, general & internal (9169) 9169
electrocardiography (8924) 8924
pharmacology & pharmacy (8872) 8872
heart attack (8719) 8719
risk (8509) 8509
peripheral vascular disease (8486) 8486
care and treatment (8373) 8373
cardiovascular (8193) 8193
myocardial infarction - physiopathology (8079) 8079
myocardial infarction - therapy (8021) 8021
myocardial infarction - mortality (7770) 7770
prognosis (7770) 7770
heart (7590) 7590
heart failure (7585) 7585
follow-up studies (7548) 7548
abridged index medicus (7406) 7406
myocardial infarction - complications (7323) 7323
prospective studies (7215) 7215
cardiovascular diseases (7075) 7075
ischemia (7018) 7018
therapy (6981) 6981
aged, 80 and over (6896) 6896
percutaneous coronary intervention (6779) 6779
cardiac patients (6661) 6661
drug therapy (6652) 6652
rats (6646) 6646
analysis (6533) 6533
coronary heart disease (6270) 6270
medicine & public health (6190) 6190
research (6062) 6062
retrospective studies (5820) 5820
health aspects (5781) 5781
thrombolytic therapy (5779) 5779
coronary angiography (5541) 5541
risk assessment (5231) 5231
hypertension (5222) 5222
platelet aggregation inhibitors - therapeutic use (5171) 5171
acute coronary syndromes (5137) 5137
atherosclerosis (5087) 5087
stroke (5067) 5067
disease (5029) 5029
diabetes (4944) 4944
myocardial infarction - etiology (4876) 4876
patients (4855) 4855
heart diseases (4816) 4816
drug therapy, combination (4775) 4775
prevention (4733) 4733
myocardial infarction - diagnosis (4727) 4727
stents (4708) 4708
coronary vessels (4644) 4644
myocardial infarction - prevention & control (4621) 4621
coronary artery disease (4558) 4558
angioplasty (4545) 4545
clinical trials as topic (4352) 4352
studies (4338) 4338
randomized controlled trials as topic (4303) 4303
myocardial infarction - pathology (4122) 4122
fibrinolytic agents - therapeutic use (4064) 4064
heart-failure (4056) 4056
thrombosis (4053) 4053
cardiovascular-disease (4052) 4052
aspirin (3989) 3989
inflammation (3988) 3988
outcomes (3980) 3980
infarction (3951) 3951
hematology (3907) 3907
disease models, animal (3869) 3869
internal medicine (3835) 3835
clinical trials (3777) 3777
management (3775) 3775
reperfusion (3749) 3749
angioplasty, balloon, coronary (3731) 3731
trial (3688) 3688
double-blind method (3641) 3641
adrenergic beta-antagonists - therapeutic use (3618) 3618
medical research (3604) 3604
heart failure - drug therapy (3584) 3584
surgery (3542) 3542
medicine, research & experimental (3538) 3538
medicine (3488) 3488
clopidogrel (3458) 3458
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (58) 58
Online Resources - Online (14) 14
Collection Dvlpm't (Acquisitions) - Vendor file (9) 9
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Gerstein Science - Circulation Desk (2) 2
Scarborough Hospital - General (2) 2
Baycrest Hospital - Wellness Library (1) 1
Robarts - Stacks (1) 1
Scarborough Hospital - Missing (1) 1
Scarborough Hospital - Online (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (95215) 95215
German (2388) 2388
Russian (1736) 1736
French (1150) 1150
Italian (805) 805
Spanish (785) 785
Japanese (690) 690
Chinese (427) 427
Polish (396) 396
Portuguese (323) 323
Danish (140) 140
Czech (131) 131
Norwegian (131) 131
Swedish (102) 102
Dutch (101) 101
Hungarian (83) 83
Turkish (49) 49
Finnish (48) 48
Hebrew (48) 48
Romanian (46) 46
Bulgarian (39) 39
Serbian (39) 39
Croatian (31) 31
Slovak (26) 26
Ukrainian (22) 22
Lithuanian (12) 12
Korean (5) 5
Afrikaans (4) 4
Persian (3) 3
Slovenian (3) 3
Arabic (2) 2
Bosnian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 12, pp. 1119 - 1131
Patients with myocardial infarction and a high-sensitivity CRP level of 2 mg or more per liter were assigned to one of three canakinumab doses or placebo... 
no | C-REACTIVE PROTEIN | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | MYOCARDIAL-INFARCTION | STATIN THERAPY | CLONAL HEMATOPOIESIS | INFLAMMATION | CARDIOVASCULAR-DISEASE | INTERLEUKIN-1-BETA INHIBITION | RISK | CORONARY-ARTERY-DISEASE | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Secondary Prevention | Infection - etiology | Incidence | Dose-Response Relationship, Drug | Anti-Inflammatory Agents - adverse effects | C-Reactive Protein - metabolism | Lipids - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Anti-Inflammatory Agents - administration & dosage | Female | Neutropenia - chemically induced | Interleukin-1beta - antagonists & inhibitors | Stroke - prevention & control | Atherosclerosis - drug therapy | Double-Blind Method | Interleukin-1beta - immunology | Atherosclerosis - blood | Myocardial Infarction - drug therapy | Antibodies, Monoclonal - administration & dosage | Aged | Myocardial Infarction - prevention & control | Myocardial infarction | Cerebral infarction | Stroke | Heart attacks | C-reactive protein | Cytokines | Clinical trials | Cardiovascular disease | Innate immunity | Inflammation | Angina | Angina pectoris | Thrombosis | Cholesterol | Disease prevention | Proteins | Arteriosclerosis | Atherosclerosis | Cardiovascular diseases | Health risk assessment | Drug therapy | Drug dosages | Klinisk medicin | Clinical Medicine
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 05/2011, Volume 123, Issue 20, pp. 2226 - 2235
Journal Article
Biomaterials, ISSN 0142-9612, 2016, Volume 83, pp. 12 - 22
...) to catalytically silence tumor necrosis factor-α (TNF-α) in vivo as a potential therapeutic for myocardial infarction (MI... 
Advanced Basic Science | Dentistry | Nanoparticles | Myocardial infarction | Deoxyribozyme (DNAzyme) | Gene regulation | Tumor necrosis factor-α (TNF-α) | APOPTOSIS | CYTOKINES | MATERIALS SCIENCE, BIOMATERIALS | ENGINEERING, BIOMEDICAL | Tumor necrosis factor-alpha (TNF-alpha) | NITRIC-OXIDE SYNTHASE | CARDIAC MYOCYTE | DELIVERY | TUMOR-NECROSIS-FACTOR | DISEASE | DYSFUNCTION | INFLAMMATORY RESPONSE | EXPRESSION | Inflammation - pathology | Tumor Necrosis Factor-alpha - genetics | Fluorescence | Gene Knockdown Techniques | Inflammation - complications | Inflammation - drug therapy | Anti-Inflammatory Agents - therapeutic use | Myocardial Infarction - physiopathology | Cell Death - drug effects | Gold - chemistry | Heart - physiopathology | Tissue Distribution - drug effects | Anti-Inflammatory Agents - pharmacology | Endocytosis - drug effects | Metal Nanoparticles - chemistry | Rats, Sprague-Dawley | Myocardial Infarction - complications | Macrophages - metabolism | Animals | Myocardial Infarction - drug therapy | Myocytes, Cardiac - drug effects | Heart - drug effects | Myocytes, Cardiac - metabolism | Macrophages - drug effects | RAW 264.7 Cells | Heart Function Tests - drug effects | Mice | DNA, Catalytic - metabolism | Drugs | Surgical implants | Gold | Disorders | In vivo methods and tests | Gene expression | deoxyribozyme (DNAzyme) | nanoparticles | gene regulation | tumor necrosis factor-α (TNF-α) | myocardial infarction
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 368, Issue 15, pp. 1379 - 1387
Reperfusion strategies with fibrinolysis or primary PCI were compared in this trial involving patients with ST-segment elevation myocardial infarction (STEMI... 
MORTALITY | SURVIVAL | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | RANDOMIZED-TRIAL | DELAYS | REPERFUSION STRATEGY | Recurrence | Myocardial Infarction - mortality | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Tissue Plasminogen Activator - therapeutic use | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Tissue Plasminogen Activator - adverse effects | Angioplasty, Balloon, Coronary | Heart Failure - prevention & control | Fibrinolytic Agents - adverse effects | Myocardial Infarction - therapy | Fibrinolytic Agents - therapeutic use | Thrombolytic Therapy - methods | Ticlopidine - adverse effects | Electrocardiography | Female | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Time-to-Treatment | Intracranial Hemorrhages - etiology | Kaplan-Meier Estimate | Ticlopidine - analogs & derivatives | Coronary Angiography | Myocardial Infarction - drug therapy | Aged | Drugs | Dose-response relationship (Biochemistry) | Usage | Care and treatment | Angiography | Angioplasty | Patient outcomes | Product/Service Evaluations | Thrombolytic drugs | Heart attack | Dosage and administration | Diagnosis | Drug therapy | Myocardial infarction | Anticoagulants | Fibrin | Heart attacks | Medical imaging | Reperfusion | Clopidogrel | Congestive heart failure | Fibrinolysis | Bleeding
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2017, Volume 69, Issue 22, pp. 2710 - 2720
Abstract Background For acute myocardial infarction (AMI) without heart failure (HF), it is unclear if β-blockers are associated with reduced mortality... 
Cardiovascular | Internal Medicine | NSTEMI | preserved left ventricular systolic function | STEMI | average treatment effect | survival | propensity score | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | METOPROLOL | TRIAL | THERAPY | DISEASE | OUTCOMES | Heart Failure - complications | Myocardial Infarction - mortality | Prospective Studies | Survival Rate - trends | Follow-Up Studies | Ventricular Dysfunction - complications | Humans | Middle Aged | Ventricular Dysfunction - drug therapy | Male | Heart Failure - drug therapy | Dose-Response Relationship, Drug | Hospital Mortality - trends | Myocardial Infarction - complications | Propensity Score | Myocardial Infarction - drug therapy | Electrocardiography | Female | Registries | Aged | United Kingdom - epidemiology | Adrenergic beta-Antagonists - administration & dosage | Myocardial infarction | Heart attacks | Adjustment | Syngeneic grafts | Mortality | Cardiovascular disease | Coefficients | Patients | Survival | Beta blockers | Weighting | Ischemia | Risk assessment | Xenografts | Death | Fatalities | Infarction | Ventricle | Health risk assessment | Drug therapy | Heart diseases | PCI, percutaneous coronary intervention | CI, confidence interval | AMI, acute myocardial infarction | ATE, average treatment effect | STEMI, ST-segment elevation myocardial infarction | MINAP, Myocardial Ischaemia National Audit Project | LVSD, left ventricular systolic dysfunction | NSTEMI, non–ST-segment elevation myocardial infarction | HF, heart failure | Original Investigation
Journal Article